Liposome clearance from blood: different animal species have different mechanisms  by Liu, Dexi et al.
ELSEVIER Biochimica et Biophysica Acta 1240 (1995) 277-284 
Biochi f c~a et Biophysica A~ta 
Liposome clearance from blood: different animal species have different 
mechanisms 
Dexi Liu *, Qingru Hu, Young K. Song 
Department of Pharmaceutical Sciences, School of Pharmacy, 709 Salk Hall, Universit3' of Pittsburgh, Pittsburgh, PA 15261, USA 
Received 15 March 1995; revised 5 July 1995; accepted 28 July 1995 
Abstract 
The kinetics of blood clearance and the mechanisms of liposome uptake by the reticuloendothelial system (RES) were compared in 
two animal species (mice and rats). By employing an in situ liver perfusion technique with selected liposome compositions (PC/Chol, 
PC/Chol/PS, PC/Chol/GM~ and PC/Choi/PEG5000-PE), we demonstrated that liposomes with same lipid composition exhibited 
different blood circulation half-lives in different animal species. Although liver is the major organ responsible for the clearance of 
liposomes from blood in both animal species, the specific mechanisms differ. In mice, liposome uptake by the liver did not involve 
specific serum opsonins. In contrast, liposome uptake by the rat liver was strongly dependent on serum opsonins. Further, the activity of 
serum opsonins for a given liposome composition differed among animal species. Human serum exhibited higher opsonin activities for 
PC/Chol and PC/Chol/GM] liposomes than bovine sera, while rat serum displayed ahigh opsonizing activity for GMj liposomes and 
none for liposomes composed of PC and Chol. The opsonin activity of human serum could be removed or decreased by treatment with 
EGTA/Mg 2+, EDTA or cobra venom factor, suggesting that the activity is likely due to complement components. It is likely that C3 of 
the human complement system plays an important role in mediating the uptake of liposomes by the liver. 
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1. Introduction 
The blood clearance and tissue distribution of various 
types of liposome has been extensively studied in the past 
[1,2]. Similar to other types of drug carriers including 
polymer microspheres and lipid emulsions, injected lipo- 
somes are cleared by the phagocytic ells in the reticulo- 
endothelial system (RES) of the liver, spleen and to lesser 
extent, bone marrow and lymphoid organs [1,2]. Lipo- 
somes appear to be recognized as 'foreign bodies' by the 
immune defense system and removed from blood as poten- 
Abbreviations: Chol, cholesterol; DCP, dicetyl phosphate; DTPA-SA, 
diethytenetriamine p ntaacetic acid distearylamine complex; GM I , 
monosialoganglioside; PBS, phosphate-buffered saline; PC, phosphatidyl- 
choline; PEG-PE, poly(ethylene glycol) conjugated to dioleoylphos- 
phatidylethanolamine; PS, phosphatidylserine; RES, reticuloendothelial 
system. 
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tial pathogens. Although much progress has been made in 
manipulating their clearance kinetics by either varying the 
size or surface characteristics, the mechanisms underlying 
liposome clearance by the RES remain to be elucidated. 
It has been known for some time that size and specific 
lipid composition are critical factors in determining the 
rate of liposome clearance. Large liposomes are cleared 
more rapidly than small ones. Liposomes with negatively 
charged surfaces are generally cleared more rapidly than 
those that are neutral or positively charged. For example, 
inclusion of either phosphatidylserine or dicetylphosphate 
into liposomes composed of phosphatidylcholine (PC) and 
cholesterol (Chol) greatly increases their uptake by the 
RES and reduces their liposome circulation time in the 
blood [1-5]. However, the conclusion that liposomes with 
negatively charged surface are cleared faster than those of 
neutral or positively charged have been challenged by 
Allen et al. [6] and Gabizon and Papahadojoupolos [3], 
who demonstrated that inclusion of monosialoganglioside 
GM~ (which is also negatively charged at the physiological 
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pH) into liposomes composed of PC and Chol actually 
decreases liposome uptake by the RES and prolongs their 
circulation time in the blood. Amphipathic polyethylene 
glycols have also been demonstrated to have similar activ- 
ity in prolonging blood circulation time [7-9]. Liposomes 
that exhibit a prolonged blood circulation time have been 
called Stealth liposomes [10], sterically stabilized lipo- 
somes [11], Ninja liposomes or cryptosomes (for review, 
see [12]). With their demonstrated ability in animal models 
to extravasate from the leaky vessels in tumors and accu- 
mulate at the tumor site, the newly discovered long-cir- 
culating liposomes have spurred interest in the application 
of liposomes as drug carriers in cancer chemotherapy 
[3,5,11]. 
Although it has been amply demonstrated that long-cir- 
culating liposomes are much more efficacious in delivering 
drugs and in reducing tumor growth than conventional 
liposomes [13], the mechanism by which GM I or amphi- 
pathic PEG affects the affinity of the RES for these 
liposomes in prolonging circulation time remains unclear. 
Indeed, there is not much available information to explain 
explicitly why subtle differences in liposome composition 
cause the dramatic differences observed in the rate of 
blood clearance by the RES. The critical issue that needs 
to be addressed is how liposomes are recognized by the 
macrophages of the RES. 
To elucidate the mechanism of liposome clearance by 
the RES and thus to develop better liposome formulations 
for drug delivery, we have employed a liver perfusion 
system to examine the effect of serum on liposome uptake. 
Using two different animal species (mice and rats), we 
have examined the relationship between liposome clear- 
ance in live animals and in vitro by the perfused liver. 
Results obtained from these experiments suggest that blood 
clearance and the mechanism by which the clearance rate 
is regulated iffers among animal species. 
2. Materials and methods 
2.1. Materials 
Egg yolk phosphatidylcholine (PC), bovine brain phos- 
phatidylserine (PS) and dioleoylphosphatidylethanolamine- 
N-(poly(ethylene glycol) 5000) (PEG5000-PE) were pur- 
chased from Avanti Polar Lipids (Birmingham, AL). 
Cholesterol (Chol) was purchased from Sigma Chemical 
(St. Louis, MO). Cobra venom factor was from Quidel 
(San Diego, CA). Monosialoganglioside (GM~) was pur- 
chased from Matreya (Pleasant Gap, PA). Diethylenetri- 
aminepentaacetic acid stearylamide (DTPA-SA) [14] was a 
kind gift from Dr. Leaf Huang (Department of Pharmacol- 
ogy, University of Pittsburgh). l lllnC13 (cartier-free)was 
from New England Nuclear (Wilmington, DE). Sera used 
were freshly collected from animals except bovine serum, 
which was freshly collected from a local slaughter house 
(Rendulec Packing, McKeesport, PA), stored immediately 
at - 80°C freezer and used within two months. The frozen 
serum was thawed at 37°C and used immediately. The 
mice and rats used were purchased from Harlan Sprague 
Dawley (Indianapolis, IN). 
2.2. Preparation of liposomes 
Large multilamellar liposomes were prepared by the 
extrusion method [5]. Briefly, lipids of desired composition 
were mixed with a trace amount of I IIln-DTPA-SA (lipid 
marker). The mixture was then dried under a stream of N 2 
gas and in a vacuum desiccator for at least 2 h to remove 
organic solvent. Lipid film obtained was hydrated (10 
/zmol lipids/ml) in PBS (pH 7.4) overnight at room 
temperature. The resulting lipid suspension was extruded 
20 times through two layers of membrane filter with pore 
size of 100 nm using a LiposoFast extruder (Ottawa, 
Canada). To obtain liposomes maller than 100 nm, ex- 
truded liposomes were sonicated for 5 min (bath sonicator, 
Hicksville, NY) followed by additional extrusion through 
two layers of a membrane filter with pore size of 50 nm. 
For liposomes with larger diameters, lipid suspension was 
extruded 10 times through membrane filters with pore size 
of either 400 nm or 800 nm. Average diameter of lipo- 
somes used in most of the experiments was 100 + 20 nm 
as measured by dynamic light scattering using a Coulter 
N4SD submicron particle analyzer (Coulter Electronic, 
Hiateah, FL). 
2.3. Kinetics of blood clearance and biodistribution of 
liposomes 
Liposomes (4 /~mol lipids/kg) were injected via the 
tail vein into either mice (NIH Swiss, male, 25-30 g) or 
rats (Sprague Dawley, male 250-300 g) in a volume of 
100 /zl for mice or 200 /xl for rats. At different ime 
intervals after injection, blood samples (approx. 200 /xl) 
were collected from the rats via the tail vein. Mice were 
bled at the retro orbital sinus and killed by cervical dislo- 
cation at the desired time after liposome injection. In both 
the rats and mice, the exact volume of each blood sample 
was determined by weighing. The blood concentration of
liposomes at the various time intervals was calculated 
based on the assumption that the blood is 7.4% of the body 
weight for mice [15] and 5.4% for rats [16]. 
Distribution of liposomes into organs other than blood 
was determined 4 h after administration. Liver, spleen, 
kidney, heart and lung were collected and the radioactivity 
in each organ was counted in a gamma counter. Contami- 
nation from blood in each organ was corrected for by 
means of correction factors as described previously [5]. 
Tissue distribution studies in rats were performed in the 
same way except hat blood was collected via the portal 
vein to insure maximum removal. 
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2.4. Analysis of the effect of serum components on lipo- 
some uptake by the liver using a single pass liver perfusion 
system 
The amount of liposomes and the volume of the per- 
fusates for individual animals were based on the body 
weight and the blood volume of the animals. For rat liver 
perfusion studies, liposomes (1.2 /zmol total lipids in 120 
/zl) were incubated with 1 ml of either Krebs Henseleit 
buffer (pH 7.4) or serum for 10 min at 37°C and then 
diluted to 24 ml with Krebs Henseleit buffer. 20 ml of this 
mixture was perfused via the portal vein through the rat 
liver which had previously been washed with 20 ml of 
buffer to remove contaminating blood. For mouse liver 
perfusion studies, liposomes (0.12 /xmol total lipids in 12 
/zl) from the same batch used for rats was incubated with 
0.2 ml of either buffer or serum under the same conditions 
outlined previously. The mixture was then diluted to 2.4 
ml with buffer and 2 ml of the diluted mixture was 
perfused via the portal vein through the mouse liver that 
had been pre-washed with 3 ml of buffer. Animals were 
anesthetized with ether vapor during cannulation. The 
inferior vena cava was cut to drain blood after the catheter 
had been inserted into the portal vein. This was immedi- 
ately followed by washing with buffer and subsequent 
perfusion with liposomes. Liposomes were passed through 
the liver only once and any unbound liposomes were 
removed by washing the perfused liver with 50 ml (for 
rats) and 5 ml (for mice) of buffer. The perfusion rate used 
was 7 ml /min for rat liver and 2 ml /min for mouse liver. 
The uptake of liposomes was determined by measuring the 
'~ In  radioactivity retained in the perfused liver. 
3. Results  
3.1. Circulation time of liposomes in blood is both compo- 
sition and species dependent 
Based on the known pharmacokinetics of liposomes in 
vivo [1-10], four different liposome compositions were 
selected for this study. For all preparations, liposome size 
was kept approximately 100 nm to eliminate the effect of 
size on clearance and tissue distribution. The amount of 
liposomes injected to the animals was 4 /zmol total 
l ipids/kg. The average dose injected was 0.1 /zmol for 
mice (25-30 g) and 1 /zmol for rats (250-300 g). 
As shown in Fig. 1A, liposomes containing 10% of 
either GM¿ or PEG5000-PE exhibited very long circula- 
tion time in mice. However, inclusion of the same molar 
percentage of PS into liposomes resulted in rapid blood 
clearance with a half-life of less than 10 min. Liposomes 
of PC/Chol  without additional lipid components exhibited 
a circulation time shorter than those containing GM~ or 
PEG5000-PE but longer than PS containing liposomes. 
The order of longevity of blood circulation time in mice 
for the various liposome types was PC/Cho l /GMI  > 
PC/Chol /PEG5000-PE > PC/Chol  > PC/Cho l /PS .  In 
contrast, GM~ containing liposomes showed a very short 
circulation time in rats (Fig. 1B) with an estimated half-life 
in blood of less than 10 min; over 100-fold less than that 
observed in mice. Liposomes with or without PEG-PE 
displayed almost identical clearance kinetics in rats. 4 h 
after injection, about 57% of the injected dose of lipo- 
somes composed of PC/Chol  remained in the blood com- 
pared to about 52% for PEG-containing liposomes. The 
effect of PEG5000-PE in prolonging liposome circulation 
time as was observed in mice was not obvious in rats 
within the time period of our experiments (4 h). 
One common feature observed in both animal species 
was that blood circulation time of liposomes was inversely 
proportional to liposome accumulation in the RES (liver 
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Fig. 1. Blood clearance of liposomes composed of PC/Chol (O), 
PC/Chol/GM I (O), PC/Chol/PS ( • ) and PC/Chol/PEG-PE (zx ) in 
mice (A) and rats (B). iii In-labeled liposomes with an average diameter 
of 100 nm were intravenously injected to animals at a dose of 4 
/zmol/kg. Blood concentration f liposomes at different time intervals 
was analyzed by measurement of the radioactivity of I I J In in blood 
samples ( ee Section 2 for detail). 
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Table 1 
Tissue distribution of liposomes 
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Liposome composition (molar atio) Animal species % Injected ose 
liver spleen other " 
PC/Chol (6:3) rat 16.0 + 1.1 1.8 + 0.1 0.4 + 0.3 
mouse 43.4 ± 2.6 8.9 ± 1.7 0.9 4- 0.3 
PC/Chol /PS (6:3:1) rat 79.0 4- 1.1 4.4 ± 0.8 0.1 ± 0.0 
mouse 67.5 4- 4.5 18.4 ± 3.5 0.3 ± 0.1 
PC/Cho l /GM I (6:3:1) rat 80.3 ± 4.1 10.5 4- 2.6 0.1 ± 0.0 
mouse 7.4 ± 1.2 0.3 ± 0.1 1.9 ± 0.4 
PC/Chol/PEG5000-PE (6:3:1 ) rat 27.3 ++ 1.9 0.1 ± 0.1 0 
mouse 22.4 + 2.1 2.5 ± 1.0 1.3 ± 0.3 
I It In-DTPA-SA labeled liposomes with diameter of 100 nm were intravenously injected to animals at a dose of 4 /zmol/kg. 4 h after injection, animals 
were killed and organs were collected. The amount of liposomes in each organ was determined by measuring the total radioactivity in each organ using a 
gamma counter. Data represent average + S.D. (n = 3-5). 
a Including lung, heart and kidney. 
and spleen). As is shown in Table 1, over 80% of the total 
recovered ose of liposomes containing PS (in mice and 
rats) and GM 1 (in rats) was retained in the liver 4 h after 
administration. Minimal liposome accumulation was found 
in kidney, heart and lung. 
3.2. Mechanism of liposome uptake by the li~'er 
It is apparent from Fig. 1 that liposomes of the same 
composition can have very different blood circulation times 
in different animal species. The blood circulation time of 
liposomes is seen to be inversely proportional to the level 
of liposome accumulation i the liver (Table 1), suggesting 
that the circulation time is determined by the affinity of 
liver macrophages for the liposomes. For example, lipo- 
somes with low affinity (or low uptake) for the RES 
(PC/Chol /GM l and PC/Chol /PEG in mice, and 
PC/Chol, PC/Chol /PEG in rats) will have a relatively 
long circulation time in blood, while those with higher 
affinity for (or higher uptake by) the RES will exhibit a 
short circulation time (PS liposomes in mice, PS and GM~ 
liposomes in rats). There are two possibilities to account 
for the liposome affinity for the RES. First, liposomes may 
be directly recognized by liver macrophages. For example, 
rat liver Kupffer cells may have high affinity receptors for 
both GM l and PS liposomes, permitting their capture as 
they pass through the liver, resulting in a short blood 
circulation time. On the other hand, receptors for GMI 
liposomes may be absent on mouse Kupffer cells and thus 
these liposomes display a long blood circulation time. The 
second possibility is that the affinity of the RES for 
liposomes may be dependent on the effect of serum com- 
ponents. Upon exposure to blood, liposomes may become 
coated with serum proteins. Depending on the properties of 
the liposomes, different amounts and/or types of serum 
proteins could coat the surface. It could be either the 
amount or type of proteins bound to the surface of the 
liposomes that determines the affinity of the RES for the 
liposomes and thus, modulates the blood circulation time. 
To test these possibilities, we have developed a simple 
liver perfusion system. Under the experimental conditions, 
liposomes can be perfused through the prewashed liver 
either in the presence or absence of serum. All four 
compositions tested in vivo were studied in both perfused 
mouse and rat liver. The results of these perfusion studies 
are summarized in Table 2. For liposomes exhibiting a 
Table 2 
Effect of serum on liver uptake of liposomes 
Liposome composition (molar atio) Uptake(%) 
mouse liver rat liver 
buffer mouse serum buffer rat serum 
PC/Chol (6:3) 1.2 ± 0.1 1.9 ± 0.3 1.3 ± 0.4 1.6 + 0.6 
PC/Chol /PS (6:3:1) 19.5 ± 2.6 10.3 ± 1.5 2.1 ±0.1 4.6 ± l.l a 
PC/Cho l /GM I (6:3:1) 1.9 ± 0.5 1.3 ± 0.1 4.3 ± 0.4 8.1 _+ 0.5 b 
PC/Chol/PEG5000-PE (6:3:1) 2.6 ± 0.1 2.6 ± 0.1 1.5 ± 0.1 1.0 ± 0.1 
~l t In-labeled liposomes were incubated with either buffer or serum at 37°C for 10 min and diluted with prewarmed buffer. The mixture was then perfused 
through the liver (see Section 2 for detail). The total liposome uptake by the perfused liver was presented as the percentage of the total perfused liposomes. 
Data represent the average ± S.D. (n = 3-5). 
P < 0.05 (Student's t-test) compared with that of the same liposomes without serum incubation. 
b p < 0.001 (Student's t-test) compared with that of the same liposomes without serum incubation. 
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fairly long circulation time in either mice (PC/Chol /GMj ,  
PC /Cho l /PEG5000-PE  and PC/Cho l )  or rats 
(PC/Chol/PEG-5000-PE and PC/Chol), a very low up- 
take (~ 2%) by the perfused liver was observed. Perfu- 
sions with or without serum gave essentially the same 
results. However, for liposomes exhibiting short circula- 
tion time in vivo, an apparent difference in liposome 
uptake between mice and rats by the perfused liver was 
observed. In mice, approx. 20% of the total perfused PS 
containing liposomes was taken up by the perfused liver. 
Pre-incubating these liposomes with freshly collected 
mouse serum decreased the total liver uptake to about 
10%. These results suggest hat PS liposomes are directly 
recognized by the mouse liver macrophages, and that this 
direct recognition can be partially suppressed by serum. 
Compared to the hepatic uptake of PS liposomes in mice, 
serum caused an opposite ffect on uptake by the rat liver. 
In the absence of serum, only the basal level of PS 
liposomes were taken up by the rat liver. However, the 
total liver uptake of these same liposomes was doubled 
when serum was included, suggesting that it is the serum 
components, and not the liposomes themselves, that deter- 
mines the affinity for the RES. A similar observation was 
also made for liposomes containing GM 1 (Table 2). 
3.3. Effect of human and bovine serum on liposome uptake 
by the liver 
From the preceding, it was obvious that serum compo- 
nents are involved in mediating the liver uptake of PS and 
GM~ containing liposomes in rats. We wondered if the 
sera of other animal species would have similar activity. 
To test this possibility, human and bovine serum were 
selected as examples and tested their effects on liposome 
uptake by the liver using our perfusion system. As is 
summarized in Table 3, different degrees of serum effects 
on liposome uptake by the perfused liver were observed. 
For instance, when mouse liver was used as a model, the 
total liver uptake of liposomes composed of either 
PC/Chol or PC/Chol/GM~ was greatly increased in the 
presence of both human and bovine serum. The total 
uptake for PC/Chol liposomes by the perfused liver in the 
Table 3 
Effect of human and bovine serum on liposome uptake by liver 
Liposome composition Uptake (%) 
(molar ratio) mouse liver rat liver 
human bovine human bovine 
PC/Chol (6:3) 20.0+ 1.3 5.4+0.6 8.1 +3.1 7.9-l- 1.3 
PC/Cho l /PS  (6:3:1) 13.9___2.4 12.6+0.7 7.3-4- 1.1 6.0-t-2.0 
PC/Chol/GM~ (6:3:1) 11.6+0.3 4.8+0.3 14.2+ 1.3 8.4+0.6 
PC/Chol/PEG5000-PE 2.0-t-0.1 2.94- 1.4 1.3_+0.1 1.04-0.1 
(6:3:1) 
i tlln_labeled liposomes incubated with either human or bovine serum 
were perfused through liver under the conditions described in Section 2. 
Data analysis and presentation are the same as in Table 2 (n = 3-5). 
absence of serum is less than 2% (Table 2), and is 
increased to about 20% or 5% in the presence of human or 
bovine serum respectively. A similar increase in liposome 
uptake was also obtained for GM~-containing liposomes. 
Interestingly, both human and bovine serum decreased the 
total mouse liver uptake of liposomes containing PS (from 
20% in buffer to about 14 and 13% in human and bovine 
serum, respectively). The level of this decrease is about he 
same as that caused by the mouse serum (Table 2). When 
rat liver was used, both human and bovine serum increased 
the total uptake of liposomes composed of either PC and 
Chol or similar liposomes containing additional PS or 
GM~. In comparison to liposomes not exposed to serum, a 
more than three fold increase in the total liposome uptake 
was observed in perfused rat liver in the presence of either 
human or bovine serum. It is important to note that neither 
human nor bovine serum has a noticeable ffect on the 
uptake of PEG-PE containing liposomes regardless of the 
tested animal species (Tables 2 and 3). 
3.4. The suppressive activity of serum on the uptake of 
PS-containing liposomes by mouse liver depends on lipo- 
some size 
It is interesting to note that serum had a negative ffect 
on the total iiposome uptake by the perfused mouse liver 
when PS was included as part of the lipid composition. 
About a 50% reduction in the uptake of PS containing 
liposomes was observed when serum was present (Table 
2). Also, the negative ffect seems to be independent of 
the serum source. All the serum tested showed a similar 
activity (Table 3). We wondered if the serum effect on 
liver uptake of PS containing liposomes was size depen- 
dent since a serum effect on liposome uptake by the rat 
liver has recently been reported by us [17]. To test this 
possibility, liposomes of various diameters ranging from 
60 to 600 nm were prepared and perfused through the 
mouse liver either in the presence or absence of freshly 
collected mouse serum. As is presented in Table 4, the 
overall liver uptake of liposomes was similar for all sizes 
tested. However, a clear difference in total liposome up- 
take by the perfused liver was observed in the presence of 
serum. Serum reduced liver uptake of liposomes of aver- 
age diameter 60 to 100 nm by about 50-60%. The activity 
of serum in reducing the total liposome uptake was dra- 
matically decreased with increasing liposome diameter. 
3.5. The complement system is inL~oh, ed in the serum 
enhanced liver uptake of liposomes 
It is apparent from the data presented in Table 3 that 
human serum affects the liver uptake of liposomes com- 
posed of PC/Chol, PC/Chol /PS and PC/Cho l /GM 1. 
The complement system in rats has been suspected of 
being involved in the opsonization of liposomes [17-19]. 
To demonstrate whether this is true for human serum, we 
selected three different means of blocking complement 
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Table 4 
Liposome size dependent serum effect on liver uptake of liposomes 
containing PS 
Liposome diameter Uptake (%) Serum inhibition (%) a 
(nm) in buffer in serum 
66 (broad) 23.8_+ 1.7 9.6_+0.3 60.0 
101 (21) 19.5_+2.6 10.3_+ 1.5 47.2 
216 (68) 22.3_+0.9 17.0_+ 1.3 23.7 
395 (broad) 22.0 ± 2.5 20.2 _ 2.0 8.2 
602 (broad) 28.1 ±4.5 24.2±4.5 13.8 
ill in_labeled ' PS-containing liposomes with different diameters were 
perfused through the mouse liver after incubation with either buffer or 
freshly collected mouse serum. The diameter (SD) of liposomes was 
analyzed by the unimodal analysis in a Coulter N4SD submicron particle 
analyzer. Percent inhibition by the serum was calculated by dividing the 
difference in liposome uptake in the absence and presence of serum by 
the total liver uptake in the absence of serum (n = 3-5). 
a 
uptake in buffer(% ) - uptake in serum(%) 
Inhibition(%) = uptake in buffer(%) × 100 
activation and tested their effect on liposome uptake by 
perfused mouse liver. Human serum was treated with 
either EDTA, EGTA/Mg 2+ or cobra venom factor to 
block complement activation [20,21]. The treated serum 
was then incubated with liposomes followed by perfusion. 
The results of these experiments are presented in Fig. 2. 
For PC/Chol liposomes, treatment of human serum with 
either EDTA (blocking both the classical and alternative 
pathway), EGTA/Mg 2-- (blocking the classic pathway 
only) or cobra venom factor (eliminating C3) inhibits at 
least 80% of the serum activity. More dramatic was the 
20" 
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Fig. 2. Effect of inhibition of the complement system in human serum on 
the liposome uptake by the perfused mouse liver. For serum treatments, 
200 /xl freshly collected human serum were preincubated with either 40 
/zl of EDTA (60 raM), EGTA/Mg 2+ (60 mM/15 mM) or Cobra venom 
factor (160 units/ml) for 10 min prior to incubation with liposomes, 
Other conditions were the same as those described in the method section. 
(El) without serum, (11) with serum, (light-shaded bar) with serum 
treated with EDTA, (shaded bar) with serum treated with EGTA/Mg 2+ 
and (dark-shaded bar) with serum treated with cobra venom factor. 
effect of these treatments on GM~ liposomes. As it is 
shown in Fig. 2, serum activity in enhancing the liver 
uptake of GM] liposomes was completely blocked by all 
three treatments, proving that the complement system in 
human serum plays an important role in mediating the 
liver uptake. However, blocking complement activation 
did not have much of an effect on the activity of human 
serum in reducing the uptake of PS liposomes. This would 
suggest that the activity of serum in reducing the total liver 
uptake of PS containing liposomes by the mouse liver may 
not involve complement activation. 
4. Discussion 
It has been well documented that intravenously injected 
liposomes are cleared from blood by the RES, predomi- 
nantly by the Kupffer cells in the liver [22-24]. Liposome 
size, surface characteristics and membrane fluidity play 
important roles in affecting the clearance rate [3-5]. The 
emphasis of the present work, therefore, was not to simply 
confirm some of these conclusions, but instead to use 
selected liposome compositions to demonstrate that the 
blood circulation time (or blood clearance kinetics) of 
liposomes could be very different in different animal 
species. This point has been clearly demonstrated in Fig. 1. 
Liposomes composed of PC and Chol displayed a moder- 
ate blood half-life in mice. Inclusion of GM1 or PEG5000- 
PE into such liposomes dramatically increases their blood 
half-life, while inclusion of PS greatly decreases it. Inter- 
estingly, the clearance kinetics for these liposome compo- 
sitions were different in rats. In contrast o the moderate 
circulation time in mice, liposomes composed of PC and 
Chol showed a rather long blood circulation time in rats 
(Fig. 1B). Furthermore, instead of further prolonging the 
blood half-life, inclusion of GMI into liposomes dramati- 
cally reduced the liposome circulation time. Finally, the 
function of PEG5000-PE in prolonging blood resident time 
of liposomes observed in mice is not obvious in rats. 
Liposomes composed of PC and Chol with or without 
PEG-PE showed similar blood half-lives (Fig. 1B). 
Liposomes with a short half-life in blood accumulate 
mainly in the liver with the Kupffer cells being responsible 
for their uptake [22-24]. It is apparent from the results 
presented in Table 1 that liver Kupffer cells in mice and 
rats employ different mechanisms to remove iiposomes 
from the blood. In mice, Kupffer cells appear to be capable 
of recognizing the surface characteristics of liposomes 
without the help of serum components. In fact, serum 
appears to interfere this recognition (Tables 2 and 3). The 
function of the liver Kupffer cells of mice in recognizing 
the surface properties of liposomes appears to be shared 
with other mouse-derived macrophages. Using isolated 
mouse bone marrow cells, an elevated uptake of PS con- 
taining liposomes in the absence of serum has been 
demonstrated [25]. It has also been reported that the estab- 
lished murine macrophage-like c ll lines take up more 
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liposomes containing PS than those containing either GM l 
or PEG-PE [26]. On the contrary, recognition of liposomes 
by rat Kupffer cells appears to depend on the serum 
components. The function of rat Kupffer cells in differenti- 
ating surface properties of liposomes does not seem to be 
important in the clearance of iiposomes. This conclusion, 
although requiring testing with additional experiments, 
seems to be true based on the limited number of experi- 
ments presented in this report. Experiments designed to 
extend our understanding of the functional difference be- 
tween mouse and rat Kupffer cells are yet to be performed. 
While it is evident hat mouse Kupffer cells are capable 
of recognizing different liposomes, these cells are also able 
to recognize opsonized liposomes (Table 3). For example, 
the total liver uptake of PC/Chol and PC/Chol/GM~ 
liposomes is greatly enhanced when these liposomes are 
preincubated with human or bovine serum (Table 3). The 
total liposome uptake by perfused mouse liver increased 
approx. 10-fold when human serum was included com- 
pared to that of mouse liver when either no serum or 
mouse serum was present. These results would suggest that 
there are major difference in opsonization activity of the 
serum among different animal species. Mouse serum may 
be unique in lacking opsonization activity for liposomes 
composed of PC/Cho l ,  PC /Cho l /PS  and 
PC/Chol /GM 1. It is also important o note that the 
opsonization activity of serum varied significantly among 
different animal species. Human serum showed highest 
opsonization activities for all liposomes tested so far ex- 
cept for those containing PEG-PE. This activity appeared 
to be higher than that of bovine serum (Table 3). Rat 
serum did not appear to possess opsonization activity for 
PC/Chol liposomes (Table 2). Additionally, variability in 
the opsonization activity of serum for GM~ liposomes has 
been observed among the human subjects [27]. Such vari- 
ability, however, has not yet been found among individuals 
of mice and rat population. It is not clear for bovine since 
the bovine serum used in our experiments was from one 
single mixed batch collected from a local slaughter house. 
The physiological function of phosphatidylserine has 
been extensively studied in the past. PS is exclusively 
located at the inner leaflet of the cell membrane [28]. 
Exposure of PS on the outer surface of cells is believed to 
activate the coagulation process and cause a local blood 
clotting [28-30]. Furthermore, it has also been reported 
that exposure of PS on the outer surface of red blood cells 
results in the rapid removal of these cells from the blood 
circulation by elements of the RES [29,30]. We also found 
in rats that the clearance of PS containing liposomes was 
mediated by the activation of complement system via the 
alternative pathway. Large liposomes appear to activate the 
complement system more efficiently than small ones [17]. 
As shown in Table 4, the situation in mice was just the 
opposite, and mouse serum appeared to decrease the lipo- 
some uptake by mouse liver, suggesting that the clearance 
mechanisms between mice and rats are different. It is 
interesting to note that the negative ffect of serum on the 
uptake of PS-containing liposomes by mouse liver is also 
size dependent. As shown in Table 4, small liposomes 
seem to be more sensitive to the serum effect than large 
ones. Although the detailed mechanism for this phe- 
nomenon requires further experimentation, we believe that 
the size dependent phenomenon is related to the interaction 
between liposomes and serum components. It is possible 
that serum proteins may insert into the bilayer of small 
liposomes more easily than those with larger diameters due 
to their high curvature on the outer surface. A clear 
correlation between the amount of serum proteins bound 
and liposome diameter has previously been reported [31]. 
It is likely that more proteins may bind to the surface of 
small liposomes than large ones. The bound proteins could 
interfere with recognition or binding of the PS containing 
liposomes to the mouse Kupffer cells through a PS specific 
ligand on the surface of the Kupffer cells. The activity of 
serum in reducing the liver uptake of PS containing lipo- 
somes is likely due to a nonspecific interaction since 
mouse, bovine or human serum show almost identical 
activity (Tables 2 and 3). Lack of sensitivity to the treat- 
ments used to block complement activation (Fig. 2) would 
suggest hat serum components that are responsible for 
reducing PS liposome uptake by mouse liver are different 
from those that enhance liposome uptake. 
The opsonin activity of serum for different liposomes 
has been reported by a number of groups (for review, see 
[32]). The involvement of the complement system in op- 
sonization of liposomes containing PS [17] or dicetylphos- 
phate [18] has recently been demonstrated. We and others 
have hypothesized that complement component 3 (C3) is 
the possible opsonin and the results summarized in Fig. 2 
seem to support his hypothesis. For both PC/Chol and 
PC/Chol/GM~ liposomes, treatment of human serum with 
cobra venom factor, which is known to specifically remove 
C3 from serum, removes about 90% (for PC/Chol lipo- 
somes) and 100% (for GM 1 containing liposomes) of the 
activity from human serum. Blockade of serum activity in 
reducing liposome uptake by the liver by both EDTA and 
EGTA/Mg 2+ would suggest hat the activation of the 
complement system is through the classical pathway, indi- 
cating the involvement of anti-liposome antibodies. In the 
case of liposomes composed of PC and Chol, this would 
imply that antibodies against either phospholipids, choles- 
terol, or both are present in human serum. For GM~ 
containing liposomes, we have recently demonstrated that 
the antibodies in human serum that are responsible for the 
liver uptake of GM~ liposomes are IgM [27]. Even though 
the physiological significance of anti-lipid antibodies in 
human serum is still unknown, antibodies against phospho- 
lipids, cholesterol and different glycolipids have been found 
in humans and many other animal species (for review, see 
[33]). 
While it is evident from this report hat different animal 
species have different mechanisms to remove liposomes 
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from the blood circulation, inclusion of PEG-PE molecules 
into liposomes eems to be a very efficient way to block 
these clearance mechanisms (Fig. 1, Tables 2 and 3). The 
function of PEG on the surface of l iposomes in prolonging 
liposome circulation appeared to be two-fold. In mice, 
PEG provides steric hindrance to the binding of l iposomes 
composed of PC and Chol to the Kupffer cells possibly 
through surface receptors. Secondly, in those instances 
where complement activation is involved, PEG may either 
prevent the antibodies from binding to the surface of 
liposomes, block the activation of complement system or 
prevent he activated complement components from bind- 
ing to liposome surface. Therefore, PEG-PE containing 
liposomes, even in the presence of opsonins to the matrix 
lipids, can still avoid recognition and blood clearance by 
the RES, suggesting that PEG-PE is a good reagent for 
making long circulating liposomes. 
In summary, four major conclusions can be made from 
the results presented in this report. First, l iposomes with 
same lipid composition may have different blood half-lives 
in different animals (Fig. 1). Second, the mechanisms of 
liposome uptake by the RES, predominantly by Kupffer 
cells in the liver, may vary among different animal species 
(Tables 2 and 3). In mice, the liver uptake of liposomes is 
directly determined by the surface characteristics of lipo- 
somes and no specific serum opsonins are involved. Rapid 
removal of PS-containing liposomes from blood by the 
liver in mice is likely due to the recognition of PS by the 
Kupffer cells. In contrast to such a direct recognition 
mechanism, hepatic uptake of l iposomes in rats appears to 
depend on the serum opsonins. It is the serum opsonins 
that determine the rate of blood clearance of l iposomes in 
rats. Third, opsonin activity for a given liposome composi- 
tion may vary among animal species (Tables 2 and 3). 
Lastly, complement component C3 in human serum is 
likely to be the opsonin for liposomes composed of 
PC/Cho l  and PC/Cho l /GM 1 (Fig. 2). Given the fact that 
animals are commonly used as a model to predict the 
clinical behavior of liposomes in humans, these conclu- 
sions are important not only for our current understanding 
of the mechanism of clearance but also for choosing the 
appropriate animal model for the development of lipo- 
some-based drug delivery systems. Avoiding activation of 
the complement system or preventing the binding of C3 to 
liposomes may be critical in the future design of long 
circulating iiposomes for clinical use. 
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